Latin America In Vitro Diagnostics Market Size To Reach $5.1 Billion By 2024

The latin america IVD market is expected to reach over USD 5.1 billion by 2024, according to a new report by Grand View Research, Inc. The Latin America IVD market is expected to grow at a significant CAGR till 2024 owing to the rising prevalence of target disorders, aging population, and the presence of favorable government initiatives for early disease diagnosis. Other factors that are anticipated to boost the growth include the introduction of technologically advanced instruments and the increasing R&D initiatives for the development of disease-specific kits.

Regular testing for diabetes, cardiovascular, cancer, and sexually transmitted diseases are necessary for the timely treatments, further avoiding the risk of fatal health complications. The availability of tests for home and near patient testing is estimated to further enhance the usage rates of these devices. From November 2015, the Anvisa, which is a regulatory body for medical devices in Brazil, has started allowing the registration for HIV self-testing kits.

The increasing adoption point of care devices coupled with the increasing awareness among the healthcare professionals regarding the early diagnosis of various diseases has provided a boost to the Latin IVD market. The rising epidemic of communicable diseases in the southernpart of Latin America, the growing need for rapid and accurate diagnostics, and the changing healthcare infrastructure scenario are some of the key drivers of the Latin IVD market.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/latin-america-in-vitro-diagnostics-ivd-market

Further key findings from the study suggest:

The instrument segment is one of the most important segments of in vitro diagnostics. The presence of highly automated analyzers and the availability of over the counter products are some of the factors responsible for its significant share.
The Molecular diagnostics segment is anticipated to be the fastest growing technology over the decade. Molecular diagnostics is a transformative area of diagnostics. The continuous innovation in technology helps the physicians for critical decision making
The infectious disease segment held the largest share in 2015 over 24% owing to the presence of favorable government initiatives in association with the WHO to curb communicable diseases.
The home care segment is estimated to witness a significant growth over the forecast period. The high number of R&D initiatives undertaken by key competitors for the development of portable IVD devices with improved sensitivity and user-friendliness is a key factor attributing towards its growth.
In 2015, Brazil was the largest regional segment with a revenue generation of over USD 1.2 billion owing to the established healthcare infrastructure, growing awareness for cancer screening, and the increasing demand for genetic testing.
Peru is expected to be one of the fastest growing regions on account of the growing economic stability, high unmet clinical needs, and the rising disposable incomes
Key players operating in the Latin America IVD market are Roche Diagnostics, Abbott Laboratories, Inc., Hologic (Gen-Probe), Becton Dickinson (BD) Company, Alere, Inc., Bio-Rad Laboratories, Qiagen N.V., Inc., bioMerieux, BioQuidel Corporation, and Siemens Healthcare.

qPCR & dPCR Market Size Worth $4.33 Billion By 2026

The global real-time pcr and digital pcr market size is anticipated to reach USD 4.33 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 8.5% during the forecast period. Growing demand for Rapid Diagnostics Tests (RTDs) is one of the high impact rendering drivers for this market. The demand for RDTs is likely to witness strong growth as local governments across the globe seek to incorporate these tests to improve the diagnosis and treatment of infectious diseases.

The emergence of RDTs as an important tool in the management of infectious diseases owing to the ability to provide rapid results in remote areas with limited healthcare infrastructure is likely to fuel the growth of the Polymerase Chain Reaction (PCR) systems which are used extensively to conduct these diagnostic procedures.

In addition, high prevalence of infectious diseases is one of the major factors contributing to the market growth. According to the estimates by the World Health Organization (WHO), lower respiratory infections, diarrheal diseases, and tuberculosis were ranked among the top ten causes of deaths worldwide in 2016. New cases of other infectious diseases, such as HIV/AIDS and malaria among others continue to witness sharp increase in developing countries which is expected to substantially increase the patient population, driving the need for better diagnosis options.

Furthermore, inorganic growth strategies such as mergers and acquisitions employed by major PCR manufacturers to broaden their product portfolio and to develop novel qPCR and dPCR products is another factor expected to propel the market during the forecast period. For instance, in January 2017, RainDance Technologies, Inc. was acquired by Bio-Rad Laboratories, Inc. which is expected to strengthen the company’s position in the field of droplet digital PCR and next generation sequencing.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/real-time-pcr-qpcr-digital-pcr-dpcr-market

Further key findings from the study suggest:

qPCR held the largest market share in 2018 due to the accuracy and wide applications of the technology in quantification of gene expression, pathogen detection and microRNA analysis
Digital PCR is estimated to be the fastest growing segment due to precise quantification of target sequences
Consumables and reagents led the product segment and is likely register the fastest CAGR of 8.9% over the forecast period due strong uptake in the use of PCR kits in diagnostic tests
Research application was the largest segment in terms of value in 2018, due to wide-spread use in research areas, such as stem cells, microbiology, and agriculture
Clinical application is expected to witness robust growth over the forecast period due to the adoption of automated processes
North America held the largest market share in terms of revenue in 2018 due launch of new PCR products along with rising demand for rapid diagnostic tests
Asia Pacific is projected to register comparatively strong growth during the forecast period owing to burgeoning patient population as a result of prevalence of infectious diseases
Prominent players in the qPCR and dPCR market include Bio-Rad Laboratories; Thermo Fisher Scientific Inc.; Qiagen N.V.; Abbott Laboratories, Inc.; and others

High Resolution Melting Analysis Market Worth $131.7 Million By 2022

Global High Resolution Melting (HRM) market is expected to reach USD 131.7 billion by 2022 according to a new report by Grand View Research Inc.

Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics. According to the Genetic and Rare Diseases Center (GARD) in 2014, 10% of the U.S. population that is nearly 30 million people were suffering from genetic disorders. Some key disease statistics are reported below:

As per the estimates provided by CDC, number of acute cases of hepatitis C reported in the United States increased from 1,778 to 2,138 from 2012 to2013
According to the UNAIDS report, out of the 36.9 million people that are suffering with HIV/AIDS, 17.1 million are unaware about disease occurrence due to unavailability of testing services
As per the WHO estimates in 2015, there are over 130-150 million people suffering with HCV globally

Based on analyzing the disease trends and relatively lower treatment rates suggests that the demand for gene mutation and other genomic tests are expected to increase significantly over the next few years. Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approved some of the treatments which are designed to meet the requirements of a specific genetic makeup or the genomic profile of the patient’s tumor.

For instance, the U.S FDA has approved a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco was approved for patients reported to have a specific genetic mutation known as “G551D mutation. The number of mutations which can lead to CF is in hundreds, and the G551D mutation is responsible for nearly 4% of the cases in the U.S.

Furthermore, in 2015, the Obama administration has announced the Precision Medicine Initiative with an investment of USD 216 million in the 2016 president’s budget. This initiative is expected to positively reinforce the HRM analysis market over the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/high-resolution-melting-analysis-market

Further key findings from the study suggest:

In 2014, North America dominated the overall HRM analysis market with a share of nearly 42%. Key factors attributed are high disease prevalence rates, presence of large number of academic universities; strong pharmaceutical and biotech industry, presence of large number genetic testing centers, and rapid adoption of novel technologies for improving the healthcare outcomes.
Asia pacific is identified as the fastest growing region over the forecast period. Key reasons attributed are increasing public and private expenditure on molecular diagnostics and genetic testing, increasing prevalence of genetic disorders, and increasing burden of chronic diseases such as cancer, COPD, HIV and others.
Key market players in the High Resolution Melting analysis market include, Roche Molecular Systems, Idaho Technology Corporation, Kapa Biosystems, Thermo Fisher Scientific, Premier Biosoft and Qiagen. Furthermore, Roche Molecular Systems leads the industry with the highest R&D expenditure and commands a significant market share.

Epigenetics Market Size Worth $22.05 Billion By 2025

The global epigenetics market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. The growing prevalence of cancer and other diseases worldwide with an epigenetic modification base is expected to drive the market during the forecast period.

Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for the development of therapeutic drugs, which will work in favor of the market.

The presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.

Technology advancements in the epigenetics industry are majorly focusing on the detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in the diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/epigenetics-market

Further key findings from the study suggest:

On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics
The kits segment is expected to post a CAGR of over 20.0% due to the need for rapid and accurate detection techniques
DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. The rapid adoption of advanced techniques such as methylation-sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment
North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to the increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for the development of improved therapeutics
Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to the presence of a large target population coupled with high unmet clinical needs
Some of the major players of epigenetics market are Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation
Extensive R&D initiatives for the development of novel drugs and the presence of strong product pipeline are expected to further boost market growth over the forecast period.

Blood Culture Test Market Worth $7.3 Billion by 2026

The global blood culture test market size is expected to reach USD 7.3 billion, at a CAGR of 9.1% by 2026, according to a new report by Grand View Research, Inc. Increasing prevalence of bloodstream infections and infectious diseases is the most significant factor anticipated to propel the growth. Rising demand for advanced diagnostic techniques for the diagnosis of infectious diseases, such as sepsis, is projected to drive the growth. Thus, many manufacturing companies have begun focusing on development of advanced diagnostic instruments and consumables. For instance, Cepheid offers Xpert MRSA/SA assay that aids in accurate detection of SA and MRSA in positive blood culture specimens in about an hour.

Introduction of various government initiatives pertaining to the prevention and control of infections is likely to propel the demand for blood culture tests. According to the Centers for Disease Control and Prevention (CDC), there was 46% decrease in central line-associated bloodstream infections in U.S. between 2008 and 2013, owing to the efforts taken by the U.S. government for the prevention of Hospital-acquired Infections (HAIs).

Click the link below:
https://www.grandviewresearch.com/industry-analysis/blood-culture-tests-market

Further key findings from the report suggest:

Conventional blood culture technique was the largest revenue-grossing segment in 2018 owing to increased applications of this method in hospitals, independent clinical laboratories, and pathology laboratories
In product segment, consumables accounted for the largest market share in terms of revenue in 2018, due the product applications in diagnostics and research, with repetitive purchase, such as blood culture media, assay, kits, and reagents, adding to the revenue
Automated blood culture systems is the fastest growing segment owing to the advantages of automation, such as low chances of error and faster result generation
Molecular technology is projected to expand at the highest CAGR over the forecast period, due to rising demand for advanced products by hospitals and laboratories for diagnosis of infectious diseases
Bacterial infections accounted for the largest revenue share in 2018, due to the fact that they are the most common cause for infection in the blood
Reference laboratories is projected to expand at the highest CAGR during the study period, because there is an increase in outsourcing of blood tests by hospitals to reference laboratories
North America accounted for the largest revenue share of the blood culture test market in 2018, due to the presence of well-developed healthcare infrastructure in this region
Asia Pacific is anticipated to register the highest CAGR during the forecast period owing to increased focus of government on the prevention of infectious diseases
Few key players include Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; Danaher Corporation; Luminex Corporation; Roche; Bruker Corporation; and Abbott Laboratories.

Allergy Diagnostics & Therapeutics Market Worth $51.95 Billion By 2026

The global allergy diagnostics and therapeutics market size is expected to reach USD 51.95 billion by 2026 registering a CAGR of 6.3%, according to a new study by Grand View Research, Inc. Increasing prevalence of allergic conditions coupled with adoption of immunoassay as diagnostic test is expected to serve this market with lucrative growth opportunities. According to the report published by the World Allergy Journal in May 2014, around 300 million cases of asthma and 200 to 250 million cases of food allergies were reported. This number is expected to increase over the forecast period due to sedentary lifestyle and poor dietary habits.

Rising industrial pollution, rapid urbanization in developing countries, and increasing Greenhouse Gas (GHG) concentrations are expected to result in increased prevalence of pollen induced respiratory disorder, thereby boosting the overall market growth over the forecast period. Emergence of technologically advanced products, such as MeDALL allergen-chip for allergy determination, is further expected to propel the market growth in the years to come.

The global market is highly competitive and is led by companies including Thermo Fisher Scientific, Omega Diagnostics, Siemens Healthcare, Stallergenes Greer, Lincoln Diagnostics, bioMerieux, HOB Biotech Group, Alcon Laboratories, Hycor Biomedical, and Hitachi Chemical Diagnostics. Most of the industry participants focus on the development of advanced products and technologies to gain competitive advantage. For instance, in March 2015, Stallergenes received approval for STG 320 in Japan, which is the first sublingual immunotherapy tablet used in the treatment of house dust mite allergy.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/allergy-diagnostic-market

Further key findings from the study suggest:

Instruments product segment is anticipated to witness the highest CAGR of 12.2% from 2019 to 2025 due to high demand for analyzers and laminators for allergy diagnostics
In vitro is expected to be the largest as well as fastest-growing test segment over the estimated period on account of rising demand for minimally invasive and allergen-specific tests
Antihistamines drug class led the allergy diagnostics and therapeutics market in 2018 due to its advantages, such as non sedating nature and minimum side effects with use of second generation antihistamines in allergy treatment
Immunotherapy vaccines is expected to register the maximum CAGR from 2019 to 2025 owing to extensive R&D in the field and advent of sublingual immunotherapy tablets in the treatment of allergic rhinitis
For instance, in April 2014, the U.S. FDA approved a five-grass pollen sublingual tablet (Ex-Oralair) by Stallergenes, which is used in the treatment of pollen allergy